Skip to main content
AstraZeneca PLC logo

AstraZeneca PLC — Investor Relations & Filings

Ticker · AZN ISIN · GB0009895292 LEI · PY6ZZQWO2IZFZC3IOL08 IL Manufacturing
Open in API
Filings indexed 3,411 across all filing types
Latest filing 2021-10-15 Regulatory Filings
Country GB United Kingdom
Listing IL AZN

About AstraZeneca PLC

https://www.astrazeneca.com/

AstraZeneca PLC is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines. The company's portfolio is concentrated on several main therapy areas, including Oncology; Cardiovascular, Renal & Metabolism; and Respiratory & Immunology. AstraZeneca is committed to advancing healthcare through a robust research and development pipeline, aiming to deliver innovative medicines that address significant unmet medical needs for millions of patients worldwide. The company leverages scientific innovation to transform the future of healthcare and improve patient outcomes.

Recent filings

Filing Released Lang Actions
Imfinzi & tremelimumab improved OS in liver cancer
Regulatory Filings Classification · 99% confidence The document begins with 'RNS Number : 2136P' and is dated '15 October 2021'. It contains a headline announcing clinical trial results ('Imfinzi plus tremelimumab significantly improved overall survival in HIMALAYA Phase III trial in 1st-line unresectable liver cancer'). The content details scientific findings, quotes from R&D executives, and notes about the trial design. Crucially, it ends with boilerplate text referencing 'RNS, the news service of the London Stock Exchange' and 'This information is provided by RNS'. This structure strongly indicates a regulatory news service announcement, which is typically classified as a general Regulatory Filing (RNS) or, more specifically, an Earnings Release (ER) if it pertains to financial results. Since this is a clinical trial update (a significant corporate event but not a standard quarterly financial report), and it is explicitly distributed via RNS, the most appropriate classification is RNS, as it is a general regulatory announcement distributed through that channel, or potentially ER if the context implies it's the primary release of period-related data, but RNS is safer for non-standard regulatory news.
2021-10-15 English
AZD7442 PHIII TRIAL POSITIVE IN COVID OUTPATIENTS
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing by AstraZeneca PLC, which is a report of a foreign issuer pursuant to the Securities Exchange Act of 1934. It provides detailed information about positive Phase III trial results for AZD7442 in COVID-19 outpatients, including trial design, endpoints, and outcomes. The document is not an annual or quarterly report, nor is it an earnings release or management discussion. It is a regulatory filing providing material information about clinical trial results and company developments. The document length is over 11,000 characters and contains substantive content, not just an announcement or certification. Therefore, it fits best under Regulatory Filings (RNS), which is the category for general regulatory announcements and miscellaneous filings that do not fit other specific categories.
2021-10-12 English
AZD7442 PhIII trial positive in COVID outpatients
Regulatory Filings Classification · 98% confidence The document begins with 'RNS Number : 5779O' and is dated '11 October 2021'. It contains a press release format detailing clinical trial results (TACKLE Phase III) for a drug (AZD7442) and concludes with standard disclaimers from RNS, the news service of the London Stock Exchange. This structure strongly indicates a general regulatory announcement or press release disseminated via the RNS system. Since the content is a specific announcement of clinical trial results and not a comprehensive financial report (like 10-K or IR), nor a specific management change (MANG) or dividend notice (DIV), the most appropriate classification is the general regulatory filing category, RNS, as it serves as the primary channel for such non-standardized corporate news releases.
2021-10-11 English
ENHERTU GRANTED BTD FOR BREAST CANCER
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing by AstraZeneca PLC, which is a report of a foreign issuer pursuant to the Securities Exchange Act of 1934. It contains detailed information about the FDA granting Breakthrough Therapy Designation (BTD) for Enhertu for breast cancer, including clinical trial data, drug development program, and company background. The document is not an annual or quarterly report, nor is it an earnings release or management discussion. It is a regulatory filing providing material information about a significant development related to the company's drug pipeline and regulatory status. The document is lengthy (over 14,000 characters) and contains substantive information rather than just an announcement or certification. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2021-10-04 English
Enhertu granted BTD for breast cancer
Regulatory Filings Classification · 99% confidence The document begins with 'RNS Number : 8763N' and is dated '04 October 2021'. It contains a press release format announcing regulatory news regarding an FDA Breakthrough Therapy Designation for the drug Enhertu. The presence of the RNS identifier, the structure typical of a news announcement, and the explicit mention of RNS at the end ('This information is provided by RNS, the news service of the London Stock Exchange') strongly indicate this is a regulatory news service announcement. Since it is a general announcement of a significant event (drug designation) that doesn't fit perfectly into specific financial report categories (like 10-K, ER, or DIV), the most appropriate classification is the general regulatory filing/announcement category.
2021-10-04 English
TOTAL VOTING RIGHTS
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by AstraZeneca PLC, which is a report of a foreign issuer pursuant to the Securities Exchange Act of 1934. The content focuses on the total voting rights as of 30 September 2021, providing the number of issued shares and voting rights. It references the UK Financial Conduct Authority's Disclosure and Transparency Rule 5.6.1. The document is short (3169 characters) and primarily serves as a notification of voting rights rather than a full report or detailed financial disclosure. It does not contain financial statements or detailed analysis, nor is it a proxy solicitation or voting results announcement. Given the nature and length, this fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2021-10-01 English

Browse filings by year

34 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.